Table 4 Univariate analyses of overall survival in patients with PC
Clinical parameter | Follow-up cases (n) | Median survival (months) | 1-year cumulative survival rate (%) | HR(95%CI) | P value |
|---|---|---|---|---|---|
Differentiation | 0.000 | ||||
High | 29 | 12 | 51.7 | 4.351 (11.473–28.527) | |
Middle | 65 | 13 | 56.9 | 0.501 (12.018–13.482) | |
Low | 26 | 8 | 0 | 0.630 (6.766–9.234) | |
TNM stage | 0.000 | ||||
I | 11 | 15 | 72.7 | 1.651 (11.763–18.237) | |
II | 45 | 15 | 66.7 | 2.789 (11.534–22.466) | |
III | 46 | 10 | 26.1 | 0.751 (8.529–11.471) | |
IV | 18 | 8 | 11.1 | 1.061 (5.921–10.079) | |
Distant metastasis | 0.004 | ||||
Present | 25 | 9 | 24 | 0.389 (8.238–9.762) | |
Absent | 95 | 12 | 48.4 | 0.696 (10.636–13.364) | |
Lymph node metastasis | – | 0.000 | |||
Present | 61 | 10 | 29.5 | 0.554 (8.914–11.086) | |
Absent | 59 | 13 | 57.6 | 1.280 (10.491–15.509) | |
S100A4 | 0.000 | ||||
Positive | 89 | 10 | 24.7 | 0.471 (9.077–10.923) | |
Negative | 31 | 23 | 96.8 | 2.127 (19.831–28.169) | |
Serum CA19.9 level | 0.001 | ||||
≥ 35 U/ml | 107 | 11 | 39.3 | 0.517 (9.987–12.013) | |
< 35 U/ml | 13 | 21 | 76.9 | 2.397 (17.303–26.697) | |
S100A4/CA19.9 | 0.000 | ||||
S100A4(+)/CA19.9(+) | 83 | 10 | 22.9 | 0.504(9.012–10.988) | |
S100A4(+)/CA19.9(−) | 6 | 11 | 50.0 | 4.899(1.398–20.602) | |
S100A4(−)/CA19.9(+) | 24 | 22 | 95.8 | 1.752(19.567–26.433) | |
S100A4(−)/CA19.9(−) | 7 | 25 | 100.0 |